AbCellera’s antibody discovery platform is being mobilized to accelerate preclinical development of biologics alongside Boston biotech startup Invetx. In collaboration with AbCellera, the company is working on leveraging the success of monoclonal antibodies in humans to treat chronic diseases in animals.
Read full coverage on Endpoints News.